• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Pharmaceutical Market
    Pharmaceutical News
    Pharmaceutical Stocks
    • Pharmaceutical Market
    • Pharmaceutical News
    • Pharmaceutical Stocks
    pharmaceutical investing

    Approval of Linzess Tablets 0.25 mg in Japan for Additional Indication of Chronic Constipation

    Gabrielle Lakusta
    Aug. 21, 2018 08:42AM PST
    Pharmaceutical Investing

    Astellas Pharma (TSE:4503) and Ironwood Pharmaceuticals (Nasdaq:IRWD) announced that approval has been obtained in Japan for the guanylate cyclase-C receptor agonist Linzess Tablets 0.25 mg for the additional indication of chronic constipation. As quoted in the press release: Linzess® Tablets 0.25 mg were licensed from Ironwood and have been developed and commercialized in Japan by Astellas. It …

    Astellas Pharma (TSE:4503) and Ironwood Pharmaceuticals (Nasdaq:IRWD) announced that approval has been obtained in Japan for the guanylate cyclase-C receptor agonist Linzess Tablets 0.25 mg for the additional indication of chronic constipation.

    As quoted in the press release:

    Linzess® Tablets 0.25 mg were licensed from Ironwood and have been developed and commercialized in Japan by Astellas. It was approved in Japan in December 2016 for the indication of irritable bowel syndrome with constipation (IBS-C)2, and has been on the Japanese market since March 2017.

    This approval is based on the results of a Phase 3, double-blind, placebo-controlled, parallel group trial conducted to evaluate the efficacy and safety of linaclotide orally administered for 4 weeks in 186 Japanese patients with chronic constipation. The subjects were randomly assigned to either the linaclotide (0.5 mg) or placebo group in a 1:1 ratio. In the linaclotide group, the change in weekly mean frequency of spontaneous bowel movement (SBM)3 at 1 week after the start of administration, which was the primary endpoint, represented a statistically significant improvement as compared to the placebo group. The most common adverse event was diarrhea, and its severity was mild to moderate in all cases.

    Click here to read the full press release.

    ironwood pharmaceuticalspharmaceutical investingastellas pharmatse:4503
    The Conversation (0)

    Go Deeper

    AI Powered
    AbbVie Releases New Data Demonstrating Breadth of Its Gastroenterology Portfolio at 2023 Digestive Disease Week®

    AbbVie Releases New Data Demonstrating Breadth of Its Gastroenterology Portfolio at 2023 Digestive Disease Week®

    Salix to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024

    Salix to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Pharmaceutical Investing Stocks

    Invion Limited

     
    IVX:AU

    Cardiol Therapeutics

     
    CRDL:CA
    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×